SIXTH FRAMEWORK PROGRAMME
PRIORITY 3 - NMP
Nanotechnologies and nano-science, knowledge-based
and new production processes and devices
SPECIFIC TARGETED RESEARCH OR INNOVATION PROJECT
Project acronym: BioSys
Project full title: Intelligent Biomaterial Systems for Cardiovascular
Proposal/Contract no.: STRP 013633
Cardiovascular diseases are the most frequent cause of mortality
in Europe. Concomitant the main age of the European population
will increase significantly in the next decades. To prevent the
collapse of the health care system as a result of the unpayable
clinic cost, new strategies have to be found. Tissue engineering
is such a promising strategy to compensate the disadvantages of
conventional cardiovascular prostheses. A tissue replacement,
engineered from a patients own cells, which can grow and replace
the defective tissue, is here the superlative answer. Therefore
the objective of the BioSys project is to develop new intelligent
Starting from common polymers, a biocompatible fibre with controllable
degradation will be developed. The fibre will be tested regarding
degradation and biocompatibility. Required surface modifications
will be carried out, focusing on the improvement of biocompatibility.
Different types of 3D-textile scaffolds will be designed and produced.
As example for evaluation and implementation of the new intelligent
biomaterial, cardiovascular implants will be evaluated and tissue
The developed biomaterial will be the first material with controllable
biodegradability and improved biocompability. A material with
these properties is not yet available in Europe or in other countries.
European researchers will be the first to develop and use this
kind of intelligent biomaterial. BioSys demonstrates the competitiveness
of European life science research. The results of the project
could be transferred to other medical fields for a long term innovation.
The enhancement of knowledge in the field of tissue engineering
and the development of new biomaterial will be a huge contribution
to increase the living quality of the population of the whole
European Community, will reduce the consequential costs in the
health care system and guarantee an excellent place in further
market of tissue engineered products.